Please use this identifier to cite or link to this item:
Title: Uveal Melanoma: A European Network to Face the Many Challenges of a Rare Cancer
Author: Piperno-Neumann, Sophie
Piulats, Josep M.
Goebeler, Matthias
Galloway, Iain
Lugowska, Iwona
Becker, Jürgen
Vihinen, Pia
Van Calster, Joachim
Hadjistilianou, Theodora
Proença, Rui
Caminal, Jose
Rogasik, Muriel
Blay, Jean-Yves
Kapiteijn, Ellen
Keywords: Melanoma
Issue Date: 13-Jun-2019
Publisher: MDPI
Abstract: Uveal melanoma (UM) is the most frequent primary ocular cancer in adults, accounting for 5% of all melanomas. Despite effective treatments for the primary tumour, up to 50% of UM patients will develop metastasis, leading to a very poor prognosis and a median overall survival of 6 to 12 months, with no major improvements in the last 30 years. There is no standard oncological treatment available for metastatic UM patients, and BRAF/MEK and immune checkpoint inhibitors show disappointing results when compared to cutaneous melanoma (CM). Recent advances in biology, however, identified specific gene and chromosome alterations, potentially permitting an actively tailored surveillance strategy, and dedicated clinical studies. Being a rare cancer, UM patients have to overcome issues such as identifying referral centres, having access to information, and partnering with oncologists for specific management strategies and research priorities. Here, we describe how the EUropean Rare Adult solid CAacer Network (EURACAN) will help in addressing these challenges and accelerating international collaborations to enhance the development of innovative treatments in UM.
Note: Reproducció del document publicat a:
It is part of: Cancers, 2019, vol. 11, num. 6
Related resource:
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
cancers-11-00817-v2.pdf582.42 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons